Revenue Performance - Total revenue for Q3 2025 was $21.5 million, representing a 5% increase from $20.6 million in Q3 2024[4] - U.S. revenue was $16.1 million, while international revenue increased by 4% year-over-year to $5.4 million[4] - Total revenue for Q3 2025 was $21.489 million, a 4.5% increase from $20.561 million in Q3 2024[25] - Product revenue increased to $14.556 million in Q3 2025, up 7.5% from $13.538 million in Q3 2024[25] - The company reaffirmed its full-year revenue guidance of $91 million to $95 million, indicating approximately 13% growth[16] Profitability and Loss - Gross loss was $3.8 million, compared to a gross profit of $12.2 million in the prior year period, with total GAAP gross margin at (17.5)%[5] - Adjusted gross profit was $13.7 million, with adjusted gross margin increasing to 63.9% from 60.0% in the prior year[5] - Gross loss for Q3 2025 was $(3.757) million, compared to a gross profit of $12.233 million in Q3 2024, resulting in a gross margin of (17.5%) versus 59.5%[31] - Net loss for the quarter was $34.0 million, compared to $16.9 million in the prior year[9] - Net loss for Q3 2025 was $(33.971) million, compared to a net loss of $(16.924) million in Q3 2024, resulting in a net loss per share of $(0.13) versus $(0.08)[25] - Adjusted net loss for the nine months ended September 30, 2025, was $26.171 million, an improvement from a loss of $34.552 million in 2024[33] - Adjusted EBITDA loss was $8.1 million, an improvement from $8.4 million in the prior year[10] - Adjusted EBITDA for the three months ended September 30, 2025, was $(8.079) million, compared to $(8.445) million in 2024[33] Operating Expenses - Operating expenses were $31.4 million, up 6% from $29.5 million in the prior year[8] - Operating expenses rose to $31.377 million in Q3 2025, up from $29.479 million in Q3 2024, with R&D expenses at $8.703 million[25] - Stock-based compensation increased to $4.925 million in Q3 2025 from $4.411 million in Q3 2024[33] Cash and Assets - Cash and cash equivalents stood at $144.2 million as of September 30, 2025[12] - Cash and cash equivalents increased to $144.233 million as of September 30, 2025, compared to $88.775 million at December 31, 2024[27] - Total assets as of September 30, 2025, were $290.002 million, up from $256.082 million at December 31, 2024[27] Inventory and Write-downs - The company reported a write-down of inventories of $7.931 million for the nine months ended September 30, 2025[29] - Write-downs and write-offs of inventories and vendor advances were $17.486 million in Q3 2025, significantly higher than $97,000 in Q3 2024[33] Other Financial Metrics - Interest income for the nine months ended September 30, 2025, was $4.598 million, up from $4.023 million in 2024[33] - Depreciation and amortization expenses for the nine months ended September 30, 2025, were $6.327 million, down from $7.835 million in 2024[33] - Other income (expense), net for the nine months ended September 30, 2025, was $(2.824) million, compared to $(517,000) in 2024[33] Product Development - New product developments include the P5.1 chip moving to production and the Apollo AI chip initiating development[2]

Core Insights - Butterfly Network, Inc. reported its financial results for Q3 2025, highlighting foundational progress in its operations [1] Financial Performance - The company announced its financial results for the third quarter ended September 30, 2025 [1] - Specific financial metrics were not detailed in the provided text, but the emphasis was on the progress made during the quarter [1] Business Update - Joseph DeVivo, the President, CEO, and Chairman of Butterfly, characterized the quarter as a period of foundational progress [1]

Group 1 - Butterfly Network, Inc. is a digital health company focused on transforming care through handheld, whole-body ultrasound technology and intuitive software [1] - Joseph DeVivo, the President, CEO, and Chairman of Butterfly Network, along with Megan Carlson, the Senior Vice President and Interim CFO, will participate in a fireside chat and hold one-on-one investor meetings at the UBS Global Healthcare Conference [1]

Core Points - Butterfly Network, Inc. has achieved ISO 27001 certification, which is recognized as the leading standard for information security management systems globally [1] Company Summary - The company specializes in digital health, focusing on handheld, whole-body ultrasound technology [1] - The certification was published by the International Organization for Standardization (ISO) in collaboration with the International Electrotechnical Commission (IEC) [1]

Core Insights - Butterfly Network, Inc. (BFLY) is scheduled to release its third-quarter 2025 results on October 31, before market opening [1] - The company reported a loss of 6 cents in the last quarter, exceeding the Zacks Consensus Estimate by 14.29%, and has topped earnings estimates in the last four quarters with an average surprise of 21.91% [1] Q3 Estimates - The Zacks Consensus Estimate for Butterfly Network's revenues in Q3 2025 is $21 million, reflecting a 2.1% increase from the previous year [2] - The expected loss for the third quarter is 7 cents per share, indicating a 12.5% year-over-year improvement [2] Estimate Revision Trend - Estimates for Butterfly Network's Q3 earnings have remained stable over the past 90 days [3] Factors Influencing Q3 Performance - The company is in the second year of a strategic plan aiming for over $500 million in revenues by 2030 and break-even cash flows by the end of 2027 [4] - Product revenues are expected to benefit from strong uptake of the Butterfly iQ3 probe, both domestically and internationally, along with higher average selling prices [4] - Increased enterprise software revenues and contributions from partnerships are anticipated to enhance Software and other services sales [5] Strategic Initiatives - The introduction of Compass AI, a cloud-based enterprise software platform, is expected to simplify documentation and improve record completion [5] - Ongoing strategic initiatives like Octiv, HomeCare, and Butterfly Gardens are likely to support revenue growth [6][8] - The AI marketplace, Butterfly Gardens, has added new partners and received FDA clearance for AI-powered clinical applications, which may positively impact revenues [7] Challenges - Uncertainty regarding changes in funding and government programs may slow down customer purchasing decisions, affecting U.S. hospital and enterprise channels [9]

Core Viewpoint - Butterfly Network, Inc. is set to report its third quarter 2025 financial results on October 31, 2025, before the market opens [1]. Company Announcement - The financial results will be presented by Joseph DeVivo, the President, Chief Executive Officer, and Chairman of the Board, along with Megan Carlson, the Interim Chief Financial Officer [1]. - A conference call and webcast will be held at 8:00 a.m. following the financial results announcement [1].

Core Insights - Butterfly Network has launched an AI-powered Gestational Age tool in Malawi and Uganda to enhance maternal and fetal health through improved access to ultrasound technology [1][4] - The tool allows lower-skilled healthcare workers to estimate gestational age quickly and accurately without requiring image interpretation or extensive training [4][5] - The initiative is part of Butterfly's broader commitment to advancing maternal health in under-resourced settings, supported by the Gates Foundation and developed in collaboration with the University of North Carolina [4][5] AI-Enabled Gestational Age Tool - The AI tool addresses the critical need for affordable ultrasound technology in low-resource settings, where 92% of maternal and neonatal mortality occurs in low- and middle-income countries [2] - It enables midwives and other healthcare providers to deliver timely care by determining the appropriate gestational age for necessary medical interventions [4] Milestone Achievements - Butterfly Network has successfully deployed 1,000 handheld ultrasound probes and trained over 1,050 healthcare providers in Sub-Saharan Africa from September 2022 to December 2024 [6] - As of July 2025, 1.8 million scans have been conducted, averaging 83,000 scans monthly, demonstrating significant integration of obstetrical ultrasound services in over 697 public health facilities [6] Positive Impact on Maternal Health - Preliminary data from Kenya indicates a significant increase in women seeking antenatal care before 24 weeks, with over 90% patient satisfaction reported [9] - In South Africa, there has been a notable reduction in stillbirths and maternal mortality, with 873 appropriate referrals made for higher-level care [10][11] - The average scan time for providers has been reduced to 1.3 minutes, with a high confidence level in detecting key maternal conditions post-training [12] Technological Advancements - The latest Butterfly device, iQ3, has been approved for use in South Africa and Kenya, enhancing the quality and accessibility of POCUS [7] - Butterfly's innovations have received multiple accolades, including the Best Medical Technology at the 2024 Prix Galien USA Awards, highlighting the company's commitment to advancing healthcare technology [14]

Group 1 - Butterfly Network, Inc. (NYSE:BFLY) is recognized as a fundamentally strong penny stock, with Acadian Asset Management LLC increasing its stake by 270.5%, now holding 1,598,552 shares valued at $3,642,000 [1] - The second quarter of the fiscal year marked the highest quarterly revenue for Butterfly Network, with gross margins reaching an all-time high of 64% [2] - Analysts remain optimistic about Butterfly Network, with TD Cowen maintaining a 'Buy' rating and a price target of $3.50, driven by positive results from the POCUS-CARE trial [3] Group 2 - Butterfly Network, Inc. is a Massachusetts-based company focused on developing and commercializing ultrasound imaging solutions, founded in 2011 [4]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - AGM Group Holdings Inc. (AGMH) increased by 185% to $6.36 [3] - AlphaVest Acquisition Corp (ATMV) rose by 77% to $26.80 [3] - Brera Holdings PLC (BREA) saw a 20% increase to $30.00 [3] - Asset Entities Inc. (ASST) gained 18% to $4.54 [3] - 22nd Century Group, Inc. (XXII) also increased by 18% to $2.08 [3] - Millennium Group International Holdings Limited (MGIH) rose by 16% to $2.84 [3] - Robo.ai Inc. (AIIO) increased by 11% to $2.17 [3] - Butterfly Network, Inc. (BFLY) saw a 10% rise to $2.10 [3] - GrafTech International Ltd. (EAF) increased by 9% to $13.91 [3] - Cardlytics, Inc. (CDLX) rose by 8% to $2.99 [3] Premarket Losers - ECD Automotive Design, Inc. (ECDA) decreased by 14% to $3.70 [4] - Champions Oncology, Inc. (CSBR) fell by 8% to $6.11 [4] - Beam Global (BEEM) saw an 8% decline to $2.79 [4] - Fathom Holdings Inc. (FTHM) decreased by 8% to $2.19 [4] - Ventyx Biosciences, Inc. (VTYX) fell by 7% to $2.20 [4] - SciSparc Ltd. (SPRC) decreased by 6% to $4.35 [4] - Lightwave Logic, Inc. (LWLG) fell by 6% to $3.45 [4] - Jasper Therapeutics, Inc. (JSPR) decreased by 6% to $2.43 [4] - StableX Technologies, Inc. (SBLX) fell by 5% to $5.67 [4] - Galecto, Inc. (GLTO) decreased by 5% to $2.70 [4]

Core Insights - Butterfly Network Inc. (BFLY) shares surged 14.81% to $2.17 in after-hours trading after being named to TIME's inaugural list of the World's Top HealthTech Companies for 2025 [1] - The company had already experienced a 15.95% increase during regular trading, closing at $1.89 [1] Company Recognition - Butterfly Network was selected from thousands of HealthTech companies, evaluated based on financial performance, reputation analysis, and online engagement data [2] - The recognition underscores the company's innovation in hardware and software, aiming to enhance ultrasound accessibility [3] Product Performance - The iQ3 device from Butterfly Network won the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its market impact [3] Market Performance - Despite a 39.42% loss for 2025 so far, BFLY has gained 36.96% in the past month [4] - The stock price peaked at $4.82 on February 18, 2025, but closed at $1.89, reflecting a 60.7% decrease [4] - BFLY trades within a 52-week range of $1.66 to $13.56, with a market capitalization of $475.79 million and an average daily volume of 2.91 million shares [4]